COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-Reference-Cited by-同舟云学术

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Published:2020-03-24 Issue: Volume: Page:
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Patel Ankit B.¹,Verma Ashish¹

Affiliation:

1. Renal Division, Brigham and Women’s Hospital, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2763803/jama_patel_2020_vp_200063.pdf

Reference9 articles.

1. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72?314 cases from the Chinese Center for Disease Control and Prevention.;Wu;JAMA

2. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.;Wu;JAMA Intern Med

3. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.;Zhou;Lancet,2020

4. A pneumonia outbreak associated with a new coronavirus of probable bat origin.;Zhou;Nature,2020

5. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism.;Rice;Biochem J,2004

Cited by 339 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Long-Term Cardiovascular Impact of COVID-19: Pathophysiology, Clinical Manifestations, and Management;Cureus;2024-08-10

2. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19;Frontiers in Pharmacology;2024-07-12

3. Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient;Inflammopharmacology;2024-04-15

4. Mapping ACE2 and TMPRSS2 co-expression in human brain tissue: implications for SARS-CoV-2 neurological manifestations;Journal of NeuroVirology;2024-04-10

5. Standard of care plus telmisartan on respiratory failure due to COVID-19 (STAR-COVID trial);Minerva Cardiology and Angiology;2024-04